US 11,858,990 B2
KIR3DL2 binding agents
Laurent Gauthier, Marseilles (FR); Simon Kollnberger, Headington (GB); Benjamin Rossi, Marseilles (FR); Hélène Sicard, Marseilles (FR); Carine Paturel, Marcy l'Étoile (FR); Stéphanie Cornen, Marseilles (FR); and Stéphanie Zerbib, Marseilles (FR)
Assigned to INNATE PHARMA, Marseilles (FR)
Filed by INNATE PHARMA, Marseilles (FR)
Filed on Feb. 28, 2020, as Appl. No. 16/804,018.
Application 16/804,018 is a division of application No. 14/662,349, filed on Mar. 19, 2015, granted, now 10,577,419.
Application 14/662,349 is a continuation in part of application No. PCT/EP2013/069302, filed on Sep. 17, 2013.
Claims priority of provisional application 61/702,834, filed on Sep. 19, 2012.
Prior Publication US 2020/0199228 A1, Jun. 25, 2020
Int. Cl. A61P 35/00 (2006.01); C07K 16/28 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [G01N 33/56966 (2013.01); G01N 33/56972 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); G01N 2333/70503 (2013.01); G01N 2800/24 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7095 (2013.01)] 7 Claims
 
1. A method for the treatment of a patient having a KIR3DL2-expressing T cell lymphoma, the method comprising administering to said patient an effective amount of a composition comprising an antibody having (i) heavy chain CDRs 1, 2 and 3 (HCDR1, HCDR2, HCDR3), according to the Kabat definition, of the heavy chain variable region sequence of SEQ ID NO: 13, and (ii) light chain CDRs 1, 2 and 3 (LCDR1, LCDR2, LCDR3), according to the Kabat definition, of the light chain variable region sequence of SEQ ID NO: 14.